Biomarker analysis from phase I/II study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Gazzah, A. [1 ]
Lee, J. S. [2 ]
Wang, E. [2 ]
Ternes, N. [3 ]
Wang, H. [2 ]
Boitier, E. [3 ]
Lartigau, A. [3 ]
Chadjaa, M. [3 ]
Dib, C. [3 ]
Muzard, G. [3 ]
Valence, S. [3 ]
Remaury, A. [3 ]
Palu, C. C. [4 ]
Bauchet, A-L. [3 ]
机构：
[1] Gustave Roussy, Drug Dev Dept, Villejuif, France
[2] Sanofi, Cambridge, MA USA
[3] Sanofi, Paris, France
[4] Sanofi, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
71P
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [1] Biomarker analysis from Phase 1/2 study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)
    Gazzah, Anas
    Lee, Joon Sang
    Wang, Emma
    Ternes, Nils
    Wang, Hong
    Boitier, Eric
    lartigau, AuDe
    Chadjaa, Mustapha
    Dib, Colette
    Muzard, Gaelle
    Valence, Sandrine
    Remaury, Anne
    Palu, Cintia C.
    Bauchet, Anne-Laure
    CANCER RESEARCH, 2023, 83 (08)
  • [2] Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) tumor expression in a phase I/II study of tusamitamab ravtansine (SAR408701) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Scoazec, J-Y.
    Bauchet, A-L.
    Adam, J.
    Rochaix, P.
    MacGrogan, G.
    Kim, J. E.
    Nuciforo, P.
    Lopez-Rios, F.
    Frisman, D.
    Cesarone, G.
    Bernstein, S.
    Lee, J.
    Henry, C.
    Ozoux, M-L.
    Lefebvre, A-M.
    ANNALS OF ONCOLOGY, 2021, 32 : S1011 - S1011
  • [3] Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors
    Tabernero, J.
    Bedard, P.
    Bang, Y-J.
    Vieito, M.
    Ryu, M-H.
    Fagniez, N.
    Yoruk, S.
    Charbonnier, L.
    Soufflet, C.
    Masson, N.
    Gazzah, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S589 - S590
  • [4] Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
    Ricordel, Charles
    Barlesi, Fabrice
    Cousin, Sophie
    Cho, Byoung Chul
    Calvo, Emiliano
    Kim, Tae Min
    Helissey, Carole
    Kim, Jin-Soo
    Vieito, Maria
    Boni, Valentina
    Ghiringhelli, Francois
    Chadjaa, Mustapha
    Masson, Nina
    Soufflet, Christine
    Gazzah, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Phase I/II study of exisulind and gemcitabine in patients with recurrent advanced non-small cell lung cancer (NSCLC).
    Hoang, T
    Kim, K
    Merchant, J
    Traynor, AM
    Ahuja, HG
    Masters, GA
    McGovern, JD
    Oettel, KR
    Sanchez, FA
    Schiller, JH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 642S - 642S
  • [6] Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea
    Cho, E. K.
    Kang, J. H.
    Han, J-Y.
    Lee, J. S.
    Kim, D-W.
    Kim, S-W.
    Min, Y. J.
    Lee, K. H.
    Kim, J-H.
    Park, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy
    Cho, B. C.
    Aguado de la Rosa, C.
    Vila, L.
    Isla, D.
    Oliveira, J.
    de Castro Carpeno, J.
    Tomova, A.
    Kim, T. M.
    Blasco Cordellat, A.
    Bauchet, A-L.
    Soufflet, C.
    Bensfia, S.
    Dy, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1034 - S1035
  • [8] BIOMARKER DEVELOPMENT FOR A PHASE II STUDY OF COMBINATION EPIGENETIC THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Wrangle, John M.
    Juergens, Rosalyn A.
    Vendetti, Frank
    Coleman, Barbara
    Sebree, Rosa
    Rudek, Michelle
    Herman, James
    Rudin, Charles
    Brock, Malcolm V.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1101 - S1101
  • [9] Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC).
    Mauer, AM
    Otterson, G
    Rudin, CM
    Villalona, M
    Ansari, RH
    Szeto, L
    Vokes, EE
    CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
  • [10] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
12345